¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"High Risk Percutaneous Transluminal Angioplasty"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • percutaneous irradiation
    ÇǺΰæÀ¯Á¶»ç, °æÇÇÁ¶»ç
  • percutaneous lung tap
    ÇǺΰæÀ¯ÆóõÀÚ, °æÇÇÆóõÀÚ
  • percutaneous transhepatic bile drainage
    ÇǺΰ£°æÀ¯¾µ°³°ü¹è¾×(¼ú), °æÇǰ氣´ãÁó¹è¾×(¼ú)
  • percutaneous transhepatic cholangiography
    ÇǺΰ£°æÀ¯¾µ°³°üÁ¶¿µ(¼ú), °æÇÇ´ã°üÁ¶¿µ(¼ú)
  • percutaneous transhepatic drainage
    ÇǺΰ£°æÀ¯¹è¾×(¼ú), °æÇǰ氣¹è¾×(¼ú)
  • percutaneous umbilical blood sampling
    ÇǺΰæÀ¯ÅÈÁÙÇ÷¾×äÃë(¹ý), °æÇÇÁ¦´ëÇ÷¾×äÃë(¹ý)
  • percutaneous ureteral stent insertion
    ÇǺΰæÀ¯¿ä°ü½ºÅÙÆ®»ðÀÔ(¼ú)
  • percutaneous venous catheter sampling
    ÇǺΰæÀ¯Á¤¸ÆÄ«Å×ÅÍÇ÷¾×äÃë(¹ý), °æÇÇÁ¤¸ÆÄ«Å×ÅÍÇ÷¾×äÃë(¹ý)
  • attributable risk
    ±âÀÎÀ§Çèµµ
  • absolute risk model
    Àý´ëÀ§Çè¸ðÇü
  • behavioral risk factor
    ÇൿÀ§Çè¿äÀÎ
  • empiric risk
    °æÇèÀûÀ§Çèµµ
  • low risk group
    ÀúÀ§Ç豺
  • physical hazard risk
    ¹°¸®ÀûÀ¯ÇØÀ§Çèµµ
  • population attributable risk
    ¸ðÁý´Ü±âÀÎÀ§Çèµµ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • attributable risk
    ±â¿©À§Çèµµ
  • relative risk
    ºñ±³À§Çèµµ
  • surgical risk
    ¼ö¼úÀ§Çèµµ
  • high resolution computed tomography
    °íÇØ»óÀü»ê´ÜÃþÃÔ¿µ¼ú
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • percutaneous
    °æÇÇ-, ÇǺΰæÀ¯-
  • percutaneous test
    °æÇǰ˻ç
  • percutaneous lung tap
    °æÇǼºÆóõÀÚ
  • percutaneous umbilical blood sampling
    ÇǺΰæÀ¯ÅÈÁÙÇ÷¾×äÃë¹ý, °æÇÇÁ¦´ëÇ÷¾×äÃë¹ý
  • percutaneous venous catheter sampling
    °æÇÇÁ¤¸ÆÄ«Å×ÅÍÇ÷¾×äÃë¹ý
  • stereotactic percutaneous stimulation
    Á¤À§ÇǺΰæÀ¯ÀÚ±Ø
  • absolute risk
    Àý´ëÀ§Çè, Àý´ëÀ§Çèµµ
  • absolute risk model
    Àý´ëÀ§Çè¸ðÇü
  • acceptable risk
    Çã¿ëÀ§Çè, Çã¿ëÀ§Çèµµ
  • anesthetic risk
    ¸¶ÃëÀ§Çèµµ
  • attributable risk
    ±â¿©À§Çèµµ
  • risk assessment
    À§ÇèµµÆò°¡
  • risk benefit analysis
    À§ÇèÆíÀͺм®
  • behavioral risk factor
    ÇൿÀ§Çè¿äÀÎ
  • benefit/risk ratio
    À¯ÀÍÀ¯ÇغñÀ²
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • relative risk estimation
    »ó´ë(-Àû) À§Çèµµ ÃßÁ¤(õÏïÒ)
  • HDL (High-density lipoproteins)
    °í¹ÐµµÁö´Ü¹éÁú(ÍÔÚËÓøò·Ó±ÛÜòõ)
  • High energy phosphate
    °í¿¡³ÊÁöÀλê
  • High intensity proton flow
    °í°­µµ ¾çÀÚ À¯µ¿
  • High-density lipoprotein = HDL
    °í¹ÐµµÁö´Ü¹éÁú(ÍÔÚËÓøò·Ó±ÛÜòõ)
  • High-molecular-weight kininogen
    °íºÐÀÚ·®Å°´Ï³ëÁø
  • High-threshold cells
    °í¿ªÄ¡¼¼Æ÷(ÍÔ ö·á¬øà)
  • high altitude
    °í¼Ò
  • high altitude polycyth(a)emia
    °í¼Ò¼º ÀûÇ÷±¸Áõ°¡(Áõ)(ÍÔá¶àõîåúìϹñòÊ¥ñø) .
  • high altitude polycyth(a)emia
    °í¼Ò¼º ÀûÇ÷±¸Áõ°¡(Áõ)(Ë­ËÛËÛËøÌ´Ë´Ì¡?Ì¡) .
  • high altitude pulmonary edema
    °íÁöÆóºÎÁ¾.
  • high caloric diet
    °íÄ®·Î¸®½ÄÀÌ.
  • high cellular component
    °í¼¼Æ÷ ±¸¼º ¼ººÐ
  • high dizziness
    °í¼ÒÇö±âÁõ(Ë­ËÛ̴˻̡).
  • high dose rate
    °í¼±·®À²
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • anesthetic risk
    ¸¶ÃëÀ§Çèµµ.
  • attributable risk
    ±Í¼ÓÀ§Çèµµ.
  • benefit/risk ratio
    À¯ÀÍ/À¯ÇغñÀ².
  • coronary risk factor
    °ü(»ó)(µ¿¸Æ)ÁúȯÀ§Çè¿äÀÎ.
  • explosion risk
    Æø¹ßÀ§Ç輺.
  • operative risk
    ¼ö¼úÀ§Çèµµ(¼ö¼úÀ§ÇèŹ).
  • physical hazard =p. risk
    ½ÅüÀû À§Çè (ÊÙËøËôÌ´).
  • physical risk =physical hazard
    ½ÅüÀû À§Çè(µµ)(ËàÌ§ËøËô̴̬)
  • radiation risk
    ¹æ»ç¼±À§ÇØ, ¹æ»ç¼± À§Çè
  • radiation risk coeffecient
    ¹æ»ç¼±À§ÇèÁö¼ö
  • recurrence risk
    Àç¹ßÀ§Çè
  • relative risk
    ºñ±³À§Çèµµ
  • relative risk
    ºñ±³À§Çèµµ(ËÓË´Ëô̴̬).
  • relative risk estimation
    »ó´ë(-Àû) À§Çèµµ ÃßÁ¤(õÏïÒ)
  • risk factor
    À§ÇèÀÎÀÚ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 6 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • high-speed sedimentation equilibrium
    "°í¼Ó ħ°­ÆòÇü(ÍÔáÜöØË½øÁû¬)(¹ý,Ûö)"
  • high-temperature protection regulon
    °í¿Âº¸È£(ÍÔè®ÜÁûÞ) ·¹±Ö·Ð
  • high-temperature-short-time method
    °í¿Â ´Ü½Ã°£¹ý(ÍÔè®Ó­ãÁÊàÛö)
  • high-voltage electrophoresis
    °íÀü¾Ð Àü±â¿µµ¿(ÍÔï³äâï³Ñ¨ç¶ÔÑ)
  • very high-density lipoprotein
    Ãʰí¹Ðµµ(õ±ÍÔÚËÓø) ÁöÁú´Ü¹éÁú(ò·òõÓ±ÛÜòõ)
  • very high-lipid lipoprotein
    ÃʰíÁöÁú(õ±ÍÔò·òõ) ÁöÁú´Ü¹éÁú(ò·òõÓ±ÛÜòõ)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • percutaneous cholecystostomy
    °æÇÇÀû´ã³¶·ç¼³Ä¡¼ú
  • percutaneous drainage
    °æÇÇÀû¹è¾×¼ú
  • percutaneous ethanol injection therapy
    °æÇÇÀû¿¡Å¸³îÁÖÀÔ¿ä¹ý
  • percutaneous femoral arterial puncture
    °æÇÇÀû´ëÅ𵿸ÆÃµÀÚ
  • percutaneous fine needle aspiration
    °æÇÇÀû¹Ì¼¼Ä§ÈíÀμú
  • percutaneous gastrostomy
    °æÇÇÀûÀ§·ç¼³Ä¡¼ú
  • percutaneous jejunostomy
    °æÇÇÀû°øÀå·ç¼³Ä¡¼ú
  • percutaneous needle biopsy of kidney
    °æÇǽÅħ»ý°Ë
  • percutaneous nephrolithotomy
    °æÇÇÀû½Å¼®Á¦°Å¼ú
  • percutaneous nephrostomy
    °æÇÇÀû½Å·ç¼³Ä¡¼ú
  • percutaneous stone removal
    °æÇÇÀû°á¼® Á¦°Å¼ú
  • percutaneous transcatheter biliary biopsy
    °æÇǰæ°ü´ãµµ»ý°Ë¼ú
  • percutaneous transhepatic biliary drainage
    °æÇǰ氣´ã¹è¾×¼ú
  • percutaneous transhepatic cholangiography [=PTC]
    °æÇǰ氣´ã°üÁ¶¿µ¼ú
  • percutaneous transhepatic cholecystography
    °æÇǰ氣´ã³¶Á¶¿µ¼ú
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
PTCA percutaneous transluminal coronary angioplasty
PTRA percutaneous transluminal renal angioplasty
RPTA renal percutaneous transluminal angioplasty
HRP high-risk patient; high-risk pregnancy; histidine-rich protein; horseradish peroxidase
PTBD percutaneous transhepatic biliary drainage; percutaneous transluminal balloon dilatation
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
PTCA Percutaneous transluminal coronary balloon angioplasty
TCA Transluminal coronary angioplasty
PTCA Percutaneous Transluminal Coronary Angioplasties
PTCR Percutaneous transluminal coronary recanalization
PTSMA Percutaneous transluminal septal myocardial ablation
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • percutaneous alcohol sclerotherapy
    °æÇÇ ¾ËÄÝ °æÈ­ ¿ä¹ý, °æÇÇÀû ¾ËÄÝ °æÈ­ ¿ä¹ý
  • percutaneous balloon dilatation
    °æÇÇÀû dz¼± È®Àå¼ú
  • percutaneous cholecystostomy
    °æÇÇÀû ´ã³¶·ç ¼³Ä¡¼ú
  • percutaneous endoscopic gastrostomy
    °æÇÇÀû ³»½Ã°æÀû À§·ç¼ú
  • percutaneous femoral arterial puncture
    °æÇÇÀû ´ëÅ𠵿¸Æ õÀÚ
  • percutaneous gastrostomy
    °æÇÇÀû À§·ç ¼³Ä¡¼ú
  • percutaneous jejunostomy
    °æÇÇÀû °øÀå·ç ¼³Ä¡¼ú
  • percutaneous needle biopsy of liver
    °æÇÇ °£ ħ »ý°Ë
  • percutaneous nephrostomy
    °æÇÇÀû ½Å ·ç ¼³Ä¡¼ú
  • percutaneous stone removal
    °æÇÇÀû °á¼® Á¦°Å¼ú
  • percutaneous transcatheter biliary biopsy
    °æÇÇ °æ°ü ´ãµµ »ý°Ë¼ú
  • percutaneous transhepatic cholangiography
    °æÇÇ°æ °£´ã°ü Á¶¿µ¼ú
  • percutaneous transhepatic variceal occlusion
    °æÇÇ°æ °£Á¤¸Æ·ù Æó»ö¼ú
  • percutaneous tuberculin test
    °æÇÇÀû Åõº£¸£Ä𸰠½ÃÇè
  • percutaneous venous catheter sampling
    °æÇÇ Á¤¸Æ µµÀÚ Ç÷¾× äÃë¹ý
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
percutaneous transhepatic cholangiography Contrast radiographic examination of biliary system performed by injection through a percutaneously placed needle inserted into an intrahepatic bile duct.
(05 Mar 2000)
percutaneous umbilical blood sampling See: PUBS.
(12 Dec 1998)
nephrostomy, percutaneous The insertion of a catheter through the skin and body wall into the kidney pelvis, mainly to provide urine drainage where the ureter is not functional. It is used also to remove or dissolve renal calculi and to diagnose ureteral obstruction.
(12 Dec 1998)
diskectomy, percutaneous Percutaneous excision of a herniated or displaced intervertebral disk by posterolateral approach, always remaining outside the spinal canal. Percutaneous nucleotomy was first described by hijikata in japan in 1975. In 1985 onik introduced automated percutaneous nucleotomy which consists in percutaneous aspiration of the nucleus pulposus. It is carried out under local anaesthesia, thus reducing the surgical insult and requiring brief hospitalization, often performed on an outpatient basis. It appears to be a well-tolerated alternative to surgical diskectomy and chymopapain nucleolysis.
(12 Dec 1998)
absolute risk <statistics> The excess risk due to exposure to a specific hazard (disease, injury, etc.)
(15 Jan 1998)
acceptable risk <statistics> This relates to the potential for suffering disease or injury that will be tolerated by an individual, group, or society in exchange for the benefits of using a substance or process that will cause such disease or injury.
Acceptability of risk depends on scientific data, social, economic, and political factors, and on the perceived benefits arising from a chemical or process that creates the risk in question.
(15 Jan 1998)
attributable risk The rate of a disease or other outcome in exposed individuals that can be attributed to the exposure.
(05 Mar 2000)
cardiac risk A term to describe overall risk of developing heart disease (blockage of the coronary arteries). Typical risk factors include: diabetes, high blood pressure, prior heart attack, high cholesterol, obesity, smoking and a family history for heart attacks in parents or siblings.
(27 Sep 1997)
recurrence risk In medical genetics, the recurrence risk is the chance that a genetic (inherited) disease present in the family will recur in that family and affect another person (or persons). It is the chance of lightning striking twice (or thrice, etc.).
(12 Dec 1998)
glaucoma, risk factors If you belong to a high-risk group for glaucoma, have your eyes examined through dilated pupils every 2 years by an eye care professional. High-risk groups include everyone with a family history of glaucoma, everyone over the age of 60 and any Black over the age of 40. (Among Blacks, studies show that glaucoma is: 5 times more likely to occur in Blacks than in Whites and about 4 times more likely to cause blindness in Blacks than in Whites).
(12 Dec 1998)
relative risk <epidemiology> The proportion of diseased people amongst those exposed to the relevant risk factor divided by the proportion of diseased people amongst those not exposed to the risk factor. This should be used in those cohort studies where those with and without disease are followed to observe which individuals become diseased.
(05 Dec 1998)
risk The probability that an event will occur. It encompasses a variety of measures of the probability of a generally unfavorable outcome.
(12 Dec 1998)
risk assessment The qualitative or quantitative estimation of the likelihood of adverse effects that may result from exposure to specified health hazards or from the absence of beneficial influences.
(12 Dec 1998)
risk benefit An analysis of risk versus benefit is a complex assessment that must be made by a physician prior to the administration of a particular form of drug therapy. Since many medications may have side effects that can be harmful (during the course of treatment), the overall risk of a particular form of drug therapy must be weighed against the overall threat of the untreated disease process (or treatment with an altenative drug).
(27 Sep 1997)
risk factor <statistics> A clearly defined occurrence or characteristic that has been associated with the increased rate of a subsequently occurring disease.
(14 Oct 1997)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • high time
    ²À ¾Ë¸ÂÀº ¶§
  • high-colored
    ¼±¸íÇÑ »öÁ¶ÀÇ
  • high-coloured
    ¼±¸íÇÑ »öÁ¶
  • high-muck-a-muck
    ³ôÀº »ç¶÷
  • high-muckety-muck
    ³ôÀº »ç¶÷
  • high-spirited
    ±â¿îÂù
  • high-tone
    °¡¶ôÀÌ ³ôÀº
  • high-toned
    °¡¶ôÀÌ ³ôÀº
  • High Dutch
    =High German
  • High Street
    Å«(¹øÈ­ÇÑ) °Å¸®
  • Lord High Chancellor
    ´ë¹ý°ü
  • Middle High German
    Áß¼¼(Áß±â) °íÁö µ¶ÀϾî(12-15¼¼±â)
  • Old High German
    =GERMAN
  • contact high
    °¨¿°(°£Á¢) µµÃë(¸¶¾àµµÃëÀÚ¿Í Á¢Çϰųª ¿¬±â³¿»õ·Î ÃëÇϱâ)
  • extremely high frequency
    (Åë½Å)ÃʰíÁÖÆÄ
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á